Odyssey Health, Inc. (ODYY) Completes Successful Phase I

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
426
Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated

- Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs
- With concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluation
- In a recent announcement, the company reported the successful completion of its Phase I clinical trial, which showed that the drug was safe and well tolerated
- Odyssey is looking to present the findings of the Phase I study to the FDA and is also preparing for the planned Phase II trial

A soft and squishy organ that can be deformed with a simple touch, the human brain is extremely sensitive. And although it is encased in a sturdy skull and surrounded by a cushioning fluid that collectively work to protect it from the external environment and forces that could easily wreak havoc, it is still vulnerable to extremities. In fact, blows, jolts, violent shaking, or rapid decelerations as a result of an accident, for example, can and do override these protections, leading to a mild form of brain injury called mTBI or concussion or mTBI, an area of interest for medical company Odyssey Health (OTC: ODYY).

Concussion Effects

After a concussion, and depending on the concussed individual, the brain undergoes changes triggered by, among others, mechanical damage to neuronal connections, chemical imbalance, and activation of inflammation-inducing immune cells (https://nnw.fm/Nom6D ), which cause such harmful responses as swelling, inflammation, and oxidative stress. mTBI also decreases blood flow to the brain, restricting glucose from traveling to the cells. To the concussed patient, these changes manifest in the form of symptoms such as dizziness, blurry vision, nausea and vomiting, headache, confusion, and, in some cases, loss of consciousness (https://nnw.fm/shZlz ).

While most of these symptoms resolve over the course of several weeks to a few months, concussions can cause long-term consequences. For one, a single concussion raises the risk of having another concussion, with the second being more severe (https://nnw.fm/YKgSG ). Relatedly, repetitive concussions are associated with the increased likelihood of developing neurodegenerative conditions such as Parkinson’s and Alzheimer’s disease, as well as chronic traumatic encephalopathy (“CTE”) (https://nnw.fm/AdeCg ).

PRV-002 Drug-Device Combination

With the concussion space representing a high unmet medical need, given there is currently no FDA-approved drug for the condition, Odyssey Health took the initiative to develop one, guided by the need to nip the harmful responses in the bud before they can trigger severe symptoms. The outcome was PRV-002, a fully synthetic, non-naturally occurring neurosteroid.

The drug formulation is designed to be administered into the upper nasal cavity a few minutes after a concussion, using the company’s patent-pending intranasal delivery device for onward travel to the brain along the cranial nerve. This route of administration, coupled with the drug’s lipophilic characteristics, enables PRV-002 to cross the blood-brain barrier within five minutes and spread throughout the brain within 30 minutes, reversing the harmful responses.

PRV-002 has been the subject of ongoing clinical trials as part of a drug development program that, so far, has included preclinical animal studies and a clinical study. Animal studies evidenced that PRV-002 rapidly eliminates swelling, oxidative stress, and inflammation (https://nnw.fm/Djatg ). Motivated and having fulfilled FDA requirements, Odyssey embarked on the clinical human trial stage, announcing early last Fall that it had begun enrolling subjects for a Phase I trial to treat concussion (https://nnw.fm/Amatc ).

Successful Phase I Clinical Trial

In a recent news release published September 28, Odyssey reported the successful completion of this Phase I clinical trial, noting that the drug was safe and well tolerated throughout the study period (https://nnw.fm/oT0oC ). The trial, a double-blinded, randomized, and placebo-controlled study that comprised a total of 40 healthy human volunteers, was segmented into two stages: Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”).

The SAD stage consisted of 24 participants who were separated into three different groups, known as cohorts, and received varying doses of the drug at a ratio of 3:1 with placebo. (The treatment groups were given a low, medium, or high-single dose of PRV-002.) The MAD portion of the trial was made up of 16 subjects, separated into two cohorts, each with eight members. Each subject received a single low or high dose for five consecutive days.

The Safety Review Committee (“SRC”) then monitored the subjects after the dosing of each cohort was complete. No adverse events were noted as the drug was well-tolerated for all the cohorts. Vital signs, EKG readings, sleep patterns, and breathing functions were all normal throughout the study, while blood samples showed no alterations associated with the PRV-002 treatment. Moreover, pharmacokinetic analysis, which revealed significantly lower levels of PRV-002 in the blood than what would be expected with other routes of administration, suggested a greater delivery of the drug formulation to the brain.

“After reviewing the data from each of the cohorts, I have strong confidence that it is safe to proceed to the next clinical trial phase where PRV-002 will be administered for ten consecutive days to subjects following concussion,” commented Dallas Hack, MD, member of the SRC. “Of particular note, the overall low levels of PRV-002 in the blood supports the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. Less systemic exposure with this targeted approach promotes patient safety.”

Odyssey is currently communicating with the FDA to present the findings from the Phase I trial while simultaneously preparing for the planned Phase II trial. More specifically, the company is identifying the Phase II trial sites and is working with its medical advisors to create a study design.

For more information, visit the company’s website at www.OdysseyHealthInc.com.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://nnw.fm/ODYY

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


Odyssey Group Intl Inc (ODYY) Stock Research Links

ODYY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 140

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 84

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 67

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 267

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 72

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 144

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
Tronox Pushes Back on Creditor Restructuring Chatter Firmly

Updated Category News Views 20

A Creditor Rumor Is Not a Restructuring Plan Two creditor groups hiring law firms can make a stock chart look like it stepped on a rake, but it is not the same thing as a debt workout. That distinction is the whole point of Tronox Holdings' November 18 update. A November 17 Wall Street Journal report said two groups of creditors had retained firms described as...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 124

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 159

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading

Top 5 Most Recently Viewed Articles

San Jose Workers Ready to Strike Amid Contract Woes

Updated Category News Views 87

Strike Looms Over San Jose City Workers Can't say I blame these San Jose city workers. They're at their wits' end, caught in what's feeling like an endless round of negotiations that just aren't getting anywhere. July 29 saw hundreds of city employees packed into Strike School sessions, seriously gearing up for what's looking like a showdown with city officials. Ain't a...

Continue Reading
Foot Health Revolution: Custom Orthotic Insoles Lead Market Surge

Updated Category News Views 70

Understanding the Custom Foot Orthotic Insoles Market Growth The Custom Foot Orthotic Insoles Market is experiencing remarkable growth driven by a series of key factors. The increasing awareness surrounding foot health, including the benefits of personalized support, plays a pivotal role in this expansion. As more individuals recognize the advantages provided by custom...

Continue Reading
Columbus McKinnon Announce Regular Dividend of $0.07

Updated Category News Views 117

Columbus McKinnon Corporation Declares Quarterly Dividend Columbus McKinnon Corporation (NASDAQ: CMCO), an established leader in intelligent motion solutions for material handling, has made a significant announcement regarding its dividend. The Board of Directors has affirmed their commitment to shareholders by declaring a regular quarterly dividend of $0.07 per common...

Continue Reading
System Integration Market Set for 13.5% Growth by 2033

Updated Category News Views 74

Understanding the Growth of the System Integration Market The global system integration market plays a vital role in the technology sector by enabling the smooth integration of various subsystems, software applications, and IT infrastructures into a unified operational framework. This market is essential for businesses looking to boost productivity, streamline processes,...

Continue Reading
Zoom Earnings Report: Analysts Revise Forecasts and Outlook

Updated Category News Views 157

Anticipation Builds for Zoom's Earnings Announcement Zoom is on the brink of dropping its fourth-quarter earnings results; brace yourself for some market action come Wednesday, February 25. This isn't just any quarterly call; it could show whether Zoom still has the magic touch or if it's leaning hard on its video-chat crutch amid growing competition and changing...

Continue Reading